| Ytd | -64.56% | |
| 1y | -71.01% |
| Open | 1.28 | Prev Close | 1.31 | Low | 1.27 | High | 1.31 | Mkt Cap | 6.18M |
| Vol | 96.39K | Avg Vol | 158.16K | EPS | -1.22 | P/E | N/A | Forward P/E | -1.49 |
| Beta | 1.38 | Short Ratio | 0.22 | Inst. Own | 2.42% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 1.24 | 200-d Avg | 2.21 | 1yr Est | 19.50 |
SNOA News
Total revenue increased 60% year over year to $6.4 million Net loss per share decreased 88% compared
Sonoma Pharmaceuticals (NASDAQ:SNOA) reported quarterly losses of $(0.09) per share. This is a 88.16
Sonoma Pharmaceuticals Inc. (NASDAQ:SNOA) on Thursday posted a first-quarter loss of 9 cents per sha
Sonoma Pharmaceuticals reported record Q1 revenue, narrow loss, doubled U.S. sales and achieved posi
Clearance includes expanded claims, clearance for multiple use, and additional packaging configurati
BOULDER, CO / ACCESS Newswire / June 30, 2026 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global
Sonoma Pharmaceuticals (NASDAQ:SNOA) reported quarterly losses of $(0.33) per share which missed the
Revenues increased 48% in Q4 2026 compared to Q4 2025, and 37% in FY 2026 compared to FY 2025 United
Sonoma Pharmaceuticals (SNOA) shares slide following a $4M public offering priced at $1.35. Get the
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA - Get Free Report) was the recipient of a significant dec
US stocks mixed, Nasdaq up 100pts. Dow down 0.35%, Nasdaq up 0.56%, S&P 500 up 0.19%. Tech up 1.
Sonoma Pharmaceuticals, Inc. (the "Company" or "Sonoma Pharmaceuticals") (NASDAQ: SN
BOULDER, CO / ACCESS Newswire / April 24, 2026 / Sonoma Pharmaceuticals, Inc. (the "Company" or "Son
Sonoma Pharmaceuticals jumps over 16% in after-hours trading following the U.S. retail launch of its
Sonoma Pharmaceuticals jumps over 16% in after-hours trading following the U.S. retail launch of its
BOULDER, CO / ACCESS Newswire / March 24, 2026 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a globa
BOULDER, CO / ACCESS Newswire / March 18, 2026 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a globa
Sonoma Pharmaceuticals (NASDAQ:SNOA) reported quarterly losses of $(0.48) per share which missed the
Revenue increased 22% for the quarter ended December 31, 2025 and 33% for the nine months ended Dece
BOULDER, CO / ACCESS Newswire / January 28, 2026 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a glo
Sonoma Pharmaceuticals (NASDAQ: SNOA - Get Free Report) and Ocular Therapeutix (NASDAQ: OCUL - Get F
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA - Get Free Report)'s stock price passed above its two hun
https://www.ebs.tga.gov.au/servlet/xmlmillr6?dbid=ebs/PublicHTML/pdfStore.nsf&docid=520725&a
BOULDER, CO / ACCESS Newswire / November 13, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a gl
BOULDER, CO / ACCESS Newswire / November 6, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a glo
Sonoma Pharmaceuticals (NASDAQ:SNOA) reported quarterly losses of $(0.32) per share which missed the
Revenues increased 57% for the quarter and 38% for the six months ended September 30, 2025 compared
On October 18, 2025, Bruce Thornton was terminated as an employee and Executive Vice President and C
BOULDER, CO / ACCESS Newswire / October 14, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a glo
BOULDER, COLORADO / ACCESS Newswire / October 7, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA),
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001367083/000168316825007265/sonoma_8k.htm
BOULDER, COLORADO / ACCESS Newswire / September 25, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA
BOULDER, CO / ACCESS Newswire / August 26, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a glob
Healthcare stocks SNOA, EVOK, KALA, DNA, & SNGX soar with massive momentum gains, signaling brea
